CA3114446A1 - Recombinant polypeptides comprising modified mhc class ii dr.alpha.1 domains and methods of use - Google Patents

Recombinant polypeptides comprising modified mhc class ii dr.alpha.1 domains and methods of use Download PDF

Info

Publication number
CA3114446A1
CA3114446A1 CA3114446A CA3114446A CA3114446A1 CA 3114446 A1 CA3114446 A1 CA 3114446A1 CA 3114446 A CA3114446 A CA 3114446A CA 3114446 A CA3114446 A CA 3114446A CA 3114446 A1 CA3114446 A1 CA 3114446A1
Authority
CA
Canada
Prior art keywords
dral
domain
recombinant polypeptide
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3114446A
Other languages
English (en)
French (fr)
Inventor
Arthur Vandenbark
Roberto MEZA-ROMERO
Halina Offner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
US Department of Veterans Affairs
Original Assignee
Oregon Health and Science University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, US Department of Veterans Affairs filed Critical Oregon Health and Science University
Publication of CA3114446A1 publication Critical patent/CA3114446A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3114446A 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified mhc class ii dr.alpha.1 domains and methods of use Pending CA3114446A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741941P 2018-10-05 2018-10-05
US62/741,941 2018-10-05
PCT/US2019/054850 WO2020072992A1 (en) 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified mhc class ii drα1 domains and methods of use

Publications (1)

Publication Number Publication Date
CA3114446A1 true CA3114446A1 (en) 2020-04-09

Family

ID=68296863

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3114446A Pending CA3114446A1 (en) 2018-10-05 2019-10-04 Recombinant polypeptides comprising modified mhc class ii dr.alpha.1 domains and methods of use

Country Status (8)

Country Link
US (1) US11945855B2 (https=)
EP (1) EP3860644A1 (https=)
JP (1) JP7511551B2 (https=)
KR (1) KR102925681B1 (https=)
CN (1) CN113164573B (https=)
AU (1) AU2019355062B2 (https=)
CA (1) CA3114446A1 (https=)
WO (1) WO2020072992A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719466A1 (en) * 2023-05-26 2026-04-08 Oregon Health & Science University Treatment of cancer with drq polypeptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US8377447B2 (en) 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US20130309229A1 (en) 2011-01-28 2013-11-21 The United States Government As Represented By The Department Of Veterans Affairs Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
US9260506B2 (en) 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
JP6364352B2 (ja) 2012-01-06 2018-07-25 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
WO2015051328A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University TREATMENT OF ISCHEMIC STROKE WITH DRα1-MOG-35-55
EP3052526A4 (en) 2013-10-03 2017-04-19 Oregon Health & Science University Recombinant polypeptides comprising mhc class ii 1 domains
WO2017070569A1 (en) 2015-10-23 2017-04-27 Oregon Health & Science University Compounds that bind macrophage migration inhibitory factor
US10689446B2 (en) 2016-06-22 2020-06-23 Oregon Health & Science University Recombinant CD74 polypeptides
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
US20180271935A1 (en) 2017-03-15 2018-09-27 Oregon Health & Science University Dralpha1-mog-35-55 treatment of traumatic brain injury

Also Published As

Publication number Publication date
CN113164573A (zh) 2021-07-23
JP7511551B2 (ja) 2024-07-05
JP2022504217A (ja) 2022-01-13
EP3860644A1 (en) 2021-08-11
WO2020072992A1 (en) 2020-04-09
US20210380660A1 (en) 2021-12-09
AU2019355062B2 (en) 2025-12-18
US11945855B2 (en) 2024-04-02
CN113164573B (zh) 2024-05-31
KR20210071019A (ko) 2021-06-15
KR102925681B1 (ko) 2026-02-10
AU2019355062A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
Greer et al. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice
US20150044245A1 (en) Partial mhc constructs and methods of use
US8343500B2 (en) Peptide composition
JP3072330B2 (ja) 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
Amor et al. Encephalitogenic epitopes of myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2Ag7) mice share an amino acid motif
JP2008537736A (ja) 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子
US6464978B1 (en) Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
NO320715B1 (no) Nye peptider avledet av humant varmesjokkprotein 60, farmasoytiske preparater omfattende slike og anvendelse av de nye peptider for fremstilling av farmasoytiske preparater for behandling og forebyggelse av insulinavhengig diabetes mellitus, samt fremgangsmate og sett for diagnostisering av IDDM.
EP0922057A1 (en) Myelin oligodendrocyte glycoprotein peptides and uses thereof
US10316075B2 (en) Recombinant polypeptides comprising MHC class II α1 domains
US5776459A (en) TCR V beta 5 peptides
AU2019355062B2 (en) Recombinant polypeptides comprising modified MHC class II DRalpha1 domains and methods of use
US8461103B2 (en) Modulation of CD4+ T cell responses by a tick saliva protein, Salp15 and polypeptides derived therefrom
EP2945966B1 (en) Peptide
US10525101B2 (en) Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
Brocke et al. Inhibition of T cell proliferation specific for acetylcholine receptor epitopes related to myasthenia gravis with antibody to T cell receptor or with competitive synthetic polymers
Vainiene et al. Natural immunodominant and experimental autoimmune encephalomyelitis‐protective determinants within the lewis rat Vβ8. 2 sequence include CDR2 and framework 3 idiotopes
WO2002020047A9 (en) Chlamydial peptides and their mimics in demyelinating disease
HK1211596B (en) Peptide

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240927

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241008

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241008

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241115

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241209

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250422

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250829

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260116

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260223